Brief: Galderma Publishes New Data On Nemluvio's Safety Profile
18/06/2025 06:02
June 18 (Reuters) - GALDERMA GROUP AG GALD.S: NEW DATA DEMONSTRATE NEMLUVIO®'S (NEMOLIZUMAB) FAVORABLE SAFETY PROFILE AND SUSTAINED AND CLINICALLY MEANINGFUL IMPROVEMENTS IN SYMPTOMS OF PRURIGO NODULARIS UP TO TWO YEARS Further company coverage: GALD.S (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Galderma AG
See all newsBrief: Galderma Receives U.S. FDA Approval For Differin Epiduo Acne Gel Prescription-To-Otc Switch
Bayer down after 'mixed reception' at U.S Supreme Court
Europe Research Roundup: Asta Energy Solutions, Dassault Systemes, Nokia
Swiss stocks - Factors to watch on April 24
Skincare company Galderma posts 25.5% sales leap, driven by US market (updated)